Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05470127 · ClinicalTrials.gov registry record · NA
Evaluation of the Performance of a Novel Prostate Biopsy System Compared With Standard of Care Biopsy Needle on Quantitative and Qualitative Tissue Parameters
A NA study of Prostate CA and Prostate Disease, sponsored by Uro-1 Medical.
- Recruiting
- Registry status
- NA
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT05470127 is a NA study of Prostate CA and Prostate Disease that is actively recruiting participants, run by Uro-1 Medical. The registered enrollment target is 200 participants, above the 91-participant average among 4 other Prostate CA trials with a reported enrollment target (120% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05470127, a NA study of Prostate CA and Prostate Disease, is actively recruiting participants, sponsored by Uro-1 Medical.
- RECRUITING
- Registry status
- NA
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
Currently used biopsy devices do not predictably obtain full cores of tissue and the tissue obtained is often fragmented and disrupted making it difficult for pathological review. This post-market study will assess the utility of the SUREcore biopsy needle and the coreCARE specimen retrieval device versus a standard of care biopsy needle and the typical tissue container used in urology offices and clinics today.
Conditions Studied
Interventions
- DEVICE Prostate biopsy needle
Study Locations (1)
Georgia
- Georgia Urology - Cartersville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2022-08-01 |
| Est. Completion | 2025-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05470127
The ClinicalTrials.gov registry entry for NCT05470127 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 91-participant average among 4 other Prostate CA trials with a reported enrollment target (120% higher). The listed sponsor is Uro-1 Medical, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Prostate CA appearing as the primary indexed condition, and to 1 intervention - of which Prostate biopsy needle is the first listed.
NCT05470127 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT05470127 about?
NCT05470127 is a clinical study titled "Evaluation of the Performance of a Novel Prostate Biopsy System Compared With Standard of Care Biopsy Needle on Quantitative and Qualitative Tissue Parameters". Currently used biopsy devices do not predictably obtain full cores of tissue and the tissue obtained is often fragmented and disrupted making it difficult for pathological review. This post-market study will assess the utility of the SUREcore biopsy needle and the coreCARE specimen retrieval device ...
What is the current status of trial NCT05470127?
This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2022-08-01. Estimated completion is 2025-12.
What conditions does trial NCT05470127 study?
This clinical trial studies the following conditions: Prostate CA, Prostate Disease.
What interventions are being tested in trial NCT05470127?
The interventions under investigation include: Prostate biopsy needle (DEVICE).
Who is sponsoring clinical trial NCT05470127?
This trial is sponsored by Uro-1 Medical, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05470127 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate CA
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer
RECRUITING · Phase 1
-
FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Fezolinetant for Treating Hot Flashes in Men With Prostate Cancer
RECRUITING · Phase 2
-
Ultralow Dose PET Imaging for PSMA Expression
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.